Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. (October 2014)

• Record Type: Journal Article
• Authors: Hiramitsu, Shinya; Ishiguro, Yoshiaki; Matsuyama, Hiroyuki; Yamada, Kenji; Kato, Kazuo; Noba, Manji; Uemura, Akihisa; Matsubara, Yoshirou; Yoshida, Satoshi; Kani, Atsushi; Tokuda, Mamoru; Kato, Hisashi; Hasegawa, Kazuo; Uchiyama, Tatsushi; Matsubara, Shiro; Mori, Kazuma; Kimura, Hisashi; Shino, Kenji; Kato, Yasuchika; Ishii, Junichi
• Is Part Of: Clinical and experimental hypertension. Volume 36:Number 6(2014)
• Page Start: 433
• Page End: 440
• Publication Date: 2014-10
• Subjects: Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.3109/10641963.2013.846358
• Languages: English
• ISSNs: 1064-1963

Abstract

<abstract> <title>Abstract</title> <p>Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout. In addition, there is growing evidence of an association between high serum levels of uric acid (sUA) and cardiovascular disease (CVD). In this preliminary report, we present 12–16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD.</p> <p>Febuxostat titrated from 10 mg/day up to 40 mg/day resulted in statistically significant and clinically relevant reductions in sUA after 12–16 weeks. A "responder" level of 6.0 mg/dL or lower was achieved in 95 of 100 (95%) patients. Significant reductions in sUA were achieved regardless of the presence/absence of coexisting diseases (e.g. CVD, renal insufficiency, diabetes and obesity) or the class of antihypertensive agent being used by the patient. No serious adverse reactions were noted with febuxostat. Although allopurinol has been used generally for hyperuricemia/gout, it is excreted fully via the kidneys, restricting its use in patients with reduced renal function, and its three-times-daily administration leads to poor adherence. Based on the results of this study, febuxostat may provide an easier option than allopurinol for clinicians specializing in CVDs.</p> </abstract>